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Althoughconsiderableprogresshasbeenachievedinbreastcancerdiagnosisandtreatment,thelive-savingeﬀectofmammograph y
hashardlybeenmeasurableandthebeneﬁtoftaxanesregardedashighlyactiveisstillamatterofdebate,possiblybecausetreatment
eﬀects have hitherto been mainly determined from the solid part of the tumor, due to lack of measurability of the systemic part
of the disease. Here, we have quantiﬁed the inﬂuence on the systemic disease, cells mobilized from the solid tumor. Increased
numbersofcirculatingepithelial cellswereobservedinscreened individualsandstillhighernumbersinbreastcancer patientswith
repeated mammograms as compared to mammogram na¨ ıve individuals. Taxanes as part of the subsequent systemic treatment led
to mobilization of tumor suspect cells in up to 78% cases and the majority of relapses have occurred in these patients. Surgery-
induced activation of disseminated cells may additionally contribute to metastasis formation.
1.Introduction
In most cancers it is not the primary tumor but the me-
tastases which are responsible for fatal outcome. The pre-
requisites for metastasis formation and detection are as
follows: (1) tumor cells must leave the tumor and get into
the circulation; (2) these cells must evade destruction in
the circulation and adhere in a distant organ; (3) the cells
must grow to a metastasis of detectable size. Therefore it
would be most promising to aim at detecting the tumor
before it has been able to form metastases. Indeed, at least in
breast cancer most tumors are detected when no measurable
metastases are, yet, We added the highlighted part to the
second address. present. However, a considerable proportion
of patients during the further course of disease develop life-
threatening metastases. Screening mammography, aiming at
detecting early tumors has not yet shown convincing results
[1, 2] and may even rather extend the period of disease than
extending life time [3].
This may be due to the fact that cells can leave from the
primary tumor when it is still below the limit of detection
and it is not known at what time point these cells can
settle and regrow. In addition, diagnostic and therapeutic
approaches might contribute to mobilizing cells from the
primary tumor since it has been shown that manipulations
of the primary tumor may seed cells into the circulation [4–
6].
In order to leave the tissue, cells need to detach from the
surrounding cells which physiologically occurs during cell
division. This may be one reason, why tumors with a high
cell division rate have a higher metastatic capacity. During
detachment cell adhesion molecules such as the Epithelial
Cell Adhesion Molecule (EpCAM) are downregulated [7].
EpCAM is a cell surface adhesion protein that is frequently
expressedatahighlevelonmostsolidtumortypes,including
prostate, breast, colon, gastric, ovarian, pancreatic, and lung
cancer[8,9].Itisdetectedatthebasolateralmembraneofthe
majorityofepithelialtissuesandisfoundtobeoverexpressed2 ISRN Oncology
by a great variety of human adenocarcinomas and squa-
mous cell carcinomas [10, 11]. Compared to primary and
metastatic tissues the EpCAM expression has been reported
to be approximately 10-fold lower on the cells shed into the
circulation as part of the epithelial-mesenchymal transition,
suggesting that loss of cell-cell adhesion is a prerequisite
for tumor cell dissemination [12, 13]. However, silencing
the EpCAM gene expression decreases the proliferation,
migration,andinvasionpotentialofbreastcancercelllinesin
vitro[11] .C e l l sm a yt h e nb ef o r c e db yi n t r a t u m o r a lp r e s s u r e
into the lymphatics [14] and subsequently are drained into
blood. Lymph nodes may be an eﬀective barrier to cell
clumps but less to individual cells [15]. In order to resettle
and regrow which may occur in small vessels during slow
down of blood ﬂow and microthrombi formation [16],
tumor cells seem to re-upregulate their EpCAM expression
(mesenchymal-epithelialtransition).However,tumorcellsin
blood may also mask surface structures preventing antibody
binding [17–19] to evade the attack of the immune system
and subsequent uncovering at the site of settling may
contribute to readhesion of these cells.
We have, therefore, investigated the eﬀect of diagnostic
and therapeutic measures on the release of epithelial cells
fromnormalandmalignanttissueandthefateofthereleased
cells in blood circulation.
2.MaterialandMethods
1mL of anticoagulated peripheral blood was obtained, ac-
cording to ethics committee approval and analyzed using
the previously described microﬂuorimetric method, where
assay method stability of the sample and reproducibility have
been extensively described [20]. This volume was suﬃcient
to detect cells in the presurgery as well as the postsurgery
situation. In short, in order to compensate for shipping
delays samples were subjected to red blood cell lysis at day 2
after blood drawing (usually with 95% viability) using 10mL
of erythrocyte lysis solution (Qiagen, Hilden, Germany) for
10 minutes in the cold, spun down at 700g, and rediluted
in 1mL of PBS. 10µL of ﬂuorescein-isothiocyanate-(FITC-)
conjugatedmouseanti-EpCAM (Milteny,BergischGladbach
Germany) and 1µL of phycoerythrin-(PE-) labelled anti-
CD45 were added to 100µL of cell suspension, incubated
for 15 minutes in the dark, readjusted to 1mL and 20µLo f
this suspension were used for measuring epithelial-antigen-
positive cells.
A deﬁned volume of the cell suspension was applied
to a deﬁned area either on adhesion slides (Menzel Gl¨ aser,
Braunschweig, Germany) or into wells of Elisa plates; the
adherent cells were measured either using a Laser Scanning
Cytometer (LSC Compucyte Corporation, Cambridge, MA,
USA) and collecting the FITC-EpCAM and the PE-CD45
ﬂuorescence using photomultipliers (PMT) or using image
analysis in the ScanR (Olympus, Munich, Germany) which
both gave equivalent results. Values are displayed in scatter
grams and histograms. Both approaches enable the user
to locate cells contained within the positive population for
visual examination and to take photos and ﬂuoromicro-
graphs (Figure 1). Viability of the cells was visually detected
Figure 1: Gallery of vital (propidium iodide negative-red negative)
and dead (propidium positive-red positive) EpCAM positive cells
(green caps) provided by the automated microscopic system from a
patient sample. Of note is the highly variable EpCAMexpression on
cells from an individual patient.
and veriﬁed by Propidium Iodide (PI) staining (entering
exclusively dying cells), looking for nuclear PI stain and
surface EpCAM staining. Patients were analyzed for their
circulating epithelial tumor cell (CETC) numbers before
the actual mammography and followed during adjuvant
treatment and neoadjuvant treatment. CETCs were analyzed
at each visit if possible at intervals of three weeks. This
allowed longitudinal followup of the CETCs. Cell numbers
detected were up to thousandfold higher than the numbers
detected by the CellSearch approach. The explanations for
these discrepancies have been published [21]. These high
cell numbers allowed monitoring of CETC during therapy.
Patients were categorized according to the behavior of their
CETC into those with tenfold decrease or increase. Statistical
analyses were performed using the SPSS program, version
16.1.
3. Results
Mammography is the ﬁrst diagnostic step taken in breast
cancer screening and detection. Therefore the question
whether this measure can contribute to mobilize epithelial
cells was investigated. A screening population of 50 indi-
viduals without known mammary tumor and 20 patients
with conﬁrmed breast cancer were analysed for circulating
epithelial cells before the actual mammogram. Only 5
individuals had had no prior mammography. 4 of them
showed no circulating epithelial cells before the procedure
and one individual had a moderate number of circulating
epithelial cells (Figure 2). In contrast all 45 individuals
who had had repeated mammograms showed circulating
epithelial cells already before the procedure. Among these, 7
individuals with questionable ﬁndings (microcalciﬁcations)
had a 3-fold higher mean value and 5 individuals who had a
history of prior malignancy of other organs than the breast
had a tenfold higher mean value of circulating epithelial
cells than the 33 individuals with no known malignancy.
20 patients with conﬁrmed breast cancer had a 5-foldISRN Oncology 3
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Figure 2: Box plots of the distribution of numbers of EpCAM-
positive cells from a screening population of mammography
na¨ ıve individuals before the basic mammogram, individuals with
repeated mammograms without risk factors, individuals with
repeated mammograms with risk factors (microcalciﬁcations),
from patients with conﬁrmed breast cancer and from patients with
other conﬁrmed malignant tumors. Outliers are indicated by the
statistical program as asterisks.
higher mean value (Figure 2). Circulating epithelial cells
observed in these individuals may in part be due to previous
mammographies having been squeezed out of the mammary
gland by compression. Most surprisingly, obviously these
cells were not eliminated immediately. The 20 patients
with conﬁrmed breast cancer in whom mammograms were
performed at diﬀerent instances during therapy had a 5-fold
higher mean value than the supposedly healthy individuals
with repeated mammograms (Figure 2).
After diagnosis the next step in breast cancer is the
removal of the bulk of the tumor by surgery. We have
already shown previously that surgery can lead to a surge in
circulating epithelial cells, part of which may be tumor cells.
After surgery the numbers of circulating epithelial cells can
remain at an elevated level until systemic treatment which
almost all patients receive before or after surgery, since it is
assumed that breast cancer is a systemic disease already from
very early on. In an attempt to further dissect the impact
of such mobilized cells for ﬁnal outcome the behaviour of
the cells in the adjuvant therapy situation was compared to
that in the neoadjuvant or primary chemotherapy situation,
previously mainly reserved to patients with inoperable
tumors but now increasingly applied also in operable tumors
due to the possibility to perform breast conserving therapy.
Neoadjuvant chemotherapy includes taxanes which have
been shown to be highly eﬀective against breast cancer cells
and this was compared to the taxane-containing therapy
given as adjuvant treatment in patients with increased risk
(T2 tumors, involved lymph nodes or hormone receptor
negative, HER2/neu ± tumors). In our institution taxane is
given in three weekly cycles following 3 × FEC. In the group
of patients treated with adjuvant chemotherapy circulating
tumor cells were monitored in 70 patients. The tumor
characteristics of the patients are given in Table 1.
Analyses were performed before treatment, before each
new cycle and 3 weeks after the last cycle if possible
(Figure 3(a),a n d3(b)).
As has been reported before [22] the response to treat-
ment in this patient group either was a decrease in cell
numbers or an increase (almost always after an initial
decrease) during treatment. Cell numbers decreased in 20
(29%) patients of which 2 patients (10%) suﬀered relapse
and increased in 50 (71%) patients with 7(14%) relapses. In
the 3 patients without involved lymph nodes (10%) relapses
occurred only with increasing CETC, but relapses were more
frequent (20%) in patients with involved lymph nodes and
in patients with ER-negative tumors (23%) than with ER-
positivetumors(11%).Intheadjuvantsituationintotal9/70
(13%) patients have relapsed until now. The Kaplan-Meier
analysis is shown in Figure 4.
The Cox regression analysis revealed a nonsigniﬁcant
hazard ratio of 0.42 in patients with decreasing CETC
numbers as compared to patients with increasing CETC
numbers. With a mean follow-up time of 2.2 years (0.25
to 6.52) the time in the adjuvant treatment group is too
short to reveal a signiﬁcant diﬀerence between patients with
increasing and decreasing cell numbers.
CETC were monitored during neoadjuvant treatment in
60 patients before treatment, before each new cycle, and
before surgery. The tumor characteristics of the 60 patients
are given in Table 2.
In the neoadjuvant treatment group, 13/60 (22%) pa-
tients showed a decrease (Figure 5(a)). Among the 13
patients with decreasing CETC none suﬀered relapse, where-
as 16 (34%) of the 47 patients with increasing cell numbers
(Figure 5(b))ha v esuﬀeredrelapseduringthefollow-uptime
with a median of 2.9 years (0.27 to 6.68).
The occurrence of relapses was more pronounced in
patients with involved lymph nodes (66%) but more
frequent in patients with ER-positive tumors (52%) and
HER2/neu-negative tumors (53%) than in the adjuvant
treatment group. In contrast to adjuvant treatment the
diﬀerence in relapse-free survival in the Kaplan-Meier plot
(Figure 6) between patients with decreasing and increasing
CETC in the neoadjuvant treatment group was signiﬁcant
(P = 0.028) with a hazard ratio of 0.036 (95% conﬁdence
interval 0.022 to 1.63) and no plateau formation.
Thus in the neoadjuvant situation in total, 16/60 (27%)
patients have relapsed and until now this has occurred
exclusively in patients with circulating tumor cell numbers
increasing in spite of chemotherapy. Tumor characteristics
comprised more large tumors (72%) in the neoadjuvant
treatment group versus the adjuvant treatment group (46%)
but nodal involvement (50% versus 51%) and ER positivity
(23% versus 22%) were comparable. HER2/neu-positivity
was higher in the neoadjuvant treatment group (25% versus
11%). Total relapses in the patients treated with neoadjuvant
therapyweretwiceasfrequentastotalrelapsesinthepatients
treated with adjuvant therapy (27% versus 13%).4 ISRN Oncology
Table 1: Tumor characteristics of patients in complete remission and relapsed patients treated with adjuvant chemotherapy.
Adjuvant patients total 70
CR Relapse
Decrease Increase Decrease Increase
patients 61 18 43 Patients 9 2 7
T 1 3 11 12 0 T 15 0 5
T>1 2 872 1 T>14 2 2
T n . a . 202
N 0 3 092 1 N 03 0 3
N>0 3 092 1 N>06 2 4
N n . a . 101 N n.a.
M 0 6 11 84 3 M 09 2 7
E R p o s 4 31 33 0 E R p o s 5 2 3
E R n e g 1 751 2 E R n e g 4 0 4
ER n.a. 1 0 1 ER n.a.
HER2/neu pos 15 5 10 HER2/neu pos 3 0 3
HER2/neu neg 44 12 32 HER2/neu neg 5 2 3
H E R 2 / n e u n . a 211 H E R 2 / n e u n . a . 101
(T:T u m o rs i z e ,N: Lymph nodes, M: Metastases, ER: Estrogen receptor, n.a.: not analysed, CR: complete remission).
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Figure 3: Changes in numbers of circulating epithelial tumor suspect cells (CETCs) during an adjuvant therapy schedule of FEC and taxane;
(a) three typical examples of individual patients with a reduction in CETC and (b) three typical examples of individual patients with an
increase during taxane treatment after previous decrease in CETC during FEC treatment.
4. Discussion
The fatal event in most solid cancers is metastasis formation
for which a prerequisite is that cells leave the primary tumor
and become adherent at distant sites before they grow and
form metastases. These steps are still poorly understood.
Although the optimal approach would be to detect the
primary tumor before it starts seeding cells it is not sure
whether this aim can ever be achieved. It is assumed that
a tumor starts seeding cells from the 1 million cells level, a
size of 1mm when the tumor to date is neither unerringly
detectable by mammography nor by other approaches.
Moreover, our investigations suggest that diﬀerent diag-
nostic and therapeutic interventions can mobilize epithelial
cells. Apart from naturally occurring dissemination of tumor
cells from vascularization on and during tumor growth we
here present indications that even the earliest diagnostic
intervention, mammography, can mobilizes epithelial cells
which, even under benign conditions, seem not to be
rapidly cleared from the circulation. Numbers of circulating
epithelial cells were below the threshold of detection only in
mammography na¨ ıve women, whereas all individuals with
repeated mammograms had signiﬁcantly increased numbers
of circulating epithelial cells, thus one can speculate that
mammography leads to release of cells which can remain in
the circulation for extended times comparably to the results
reported on untransformed mammary cells in mice [23].
As long as these cells cannot perform the two subsequent
steps of adherence and regrowth, this may remain without
consequences. However, if an unknown malignant focus
is present in the breast, mammography may contribute to
early dissemination of malignant cells together with normal
epithelial cells. Thus, we observed a threefold higher number
of circulating epithelial cells in individuals with equivocalISRN Oncology 5
Table 2: Tumor characteristics of patients in complete remission and relapsed patients treated with neoadjuvant chemotherapy.
Neoadjuvant patients total 60
CR Relapse
Decrease Increase Decrease Increase
Patients 44 13 31 Patients 16 0 16
T 11 1 2 9 T 1 404
T>1 3 192 2 T>1 1 201 2
T n.a. 2 2 0 T n.a.
N 0 2 471 7 N 0 404
N>0 1 851 3 N>0 1 201 2
N n.a. 2 1 1 N n.a.
M 0 4 41 33 1 M 0 1 601 6
E R p o s 2 131 8 E R p o s 1 101 1
E R n e g 2 191 2 E R n e g 5 0 5
ER n.a. 2 1 1 ER n.a.
HER2/neu pos 22 9 13 HER2/neu pos 6 0 6
H E R 2 / n e u n e g 1 931 9 H E R 2 / n e u n e g 1 001 0
HER2/neu n.a 3 1 2 HER2/neu n.a. 0 0 0
(T:T u m o rs i z e ,N: Lymphnodes, M: Metastases, ER: Estrogen receptor, n.a.: not analysed, CR = complete remission).
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Figure 4: Kaplan-Meier relapse-free survival of 20 patients with
decreasingCETC(greenline)and50patientswithincreasingCETC
(red line) during adjuvant therapy with FEC/Tax.
mammographic ﬁndings than in individuals without any
signs of malignancy. Such mobilized cells with malignant
traitsmaybeabletosettleandformmetastases.Thissuggests
the possibility that this may be one of the reasons for the
mammographic paradox in young women with a higher
frequency of aggressive breast cancers [1, 24] and contribute
to the fact that the order of lives saved per individuals
screened with mammography for breast cancer, is only
around 1 per 1000—less than 0.1%, and that mammography
screening by itself has little detectable impact on mortality
due to breast cancer [2].
In patients monitored with mammography during the
course disease of a known breast cancer numbers of
circulating tumor suspect epithelial cells were signiﬁcantly
higher than in the two former populations which, in part
may be due to surgery which also can lead to release of
epithelial cells and may include normal as well as malignant
cells [25]; therefore, in these patients the contribution of
mammography is not clear.
Since almost all patients are treated subsequently with
adjuvant chemotherapy and we have shown previously that
also chemotherapy can lead to an increase in circulating
epithelial tumor suspect cells [22, 26], it is diﬃcult to discern
the impact of the diﬀerent manipulations. A comparison
between adjuvant and neoadjuvant chemotherapy, in which
surgery precedes or follows chemotherapy, may help to dis-
secttheinﬂuenceoftherespectivetreatment.Inordertohave
comparable treatment conditions we chose to investigate
the inﬂuence of a taxane-containing chemotherapy before
and after surgery. Increases were more frequent (50/60;
84%) during neoadjuvant therapy than during adjuvant
treatment (50/70; 72%) and occurred frequently after an
initial decrease during FEC treatment. The reincrease was
observed almost invariably during taxan therapy. Although,
also in the adjuvant treatment group the majority of relapses
occurred in the patients with increasing cell numbers, this
was exclusively the case in the neoadjuvant treatment group.
How can these results be explained? Taxanes are highly6 ISRN Oncology
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Figure 5: Changes in numbers of circulating epithelial tumor suspect cells (CETCs) during neoadjuvant therapy schedule of FEC and
taxane; (a) three typical examples of individual patients with a reduction in CETC and (b) three typical examples of individual patients with
an increase during taxane treatment after previous decrease in CETC during FEC treatment.
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Figure 6: Kaplan-Meier relapse-free survival of 13 patients with
decreasingCETC(greenline)and47patientswithincreasingCETC
(red line) during neoadjuvant therapy with FEC/Tax. Patients with
increasing CETC versus the end of therapy have a 28-fold risk of
relapse as compared with patients with decreasing CETC (P =
0.028).
eﬀective drugs [27] but they also have dark sides: the good
tumor reduction achieved in, for example, triple negative
breast cancers [28, 29] may only in part be due to cell
killing but at the same time to release of cells [26]d u et o
intratumoral vessel decompression [14]. It has been reported
that taxanes as microtubule-targeted drugs may enhance
the ability of circulating tumor cells (CTCs) to endothelial
engagement [30] during epithelial-to-mesenchymal transi-
tion and thus contribute to successful metastasis formation
[31] of cells that are not eliminated. EpCAM is assumed
to be downregulated during the journey of epithelial tumor
cells in the circulation [32]. Our recent results, however,
indicate that EpCAM rather may be masked probably by
serum proteins [19]. Leukocytes and platelets, present at the
site of microvascular cell arrest may contribute proteases
which can lead to demasking of EpCAM and thus enhance
adhesion to the endothelial wall.
The other question that arises is what the 2-fold higher
frequency of relapses in the neoadjuvant treatment group
as compared to the adjuvant treatment group is due to.
One reason may be the larger size of the tumors; however,
concentrations of disseminated cells did not surpass those
observed during adjuvant treatment. Also, lymph node
involvement was not diﬀerent. HER2/neu-expression was
more frequent in the neoadjuvant treatment group, but
all HER2/neu-positive patients were additionally and/or
subsequently treated with trastuzumab and relapses were
nonsigniﬁcantly more frequent in patients with HER2/neu-
negative than with HER2/neu-positive tumors. The main
diﬀerence between the two treatment schedules is the timing
of surgery. Surgery may help disseminated cells to escape
[33] from their resting stage [34] due to the activity of
diﬀerent activating factors like Vascular Endothelial Growth
Factor (VEGF) and cytokines, induced by the wound healing
process.
Itisnoticeablethatrelapsesintheneoadjuvanttreatment
group did not only occur early after surgery and showed
no plateau but continued to occur even more than 5 years
after the initial diagnosis. Careful review of the late relapses
revealed that until now all the late relapses occurred in
patients scheduled for tamoxifen therapy after surgery and
who had ﬁnished their 5 years of hormone treatment. They
had shown increasing numbers of tumor suspect cells after
the end of hormone blocking therapy. Thus, cells which may
alreadyhavesettledandstartedtogrowmayhavebeenstalled
by hormone treatment and obviously were able to rapidly
restart growing after the end of hormone blocking therapy.ISRN Oncology 7
The increase in cell numbers in patients with conﬁrmed
breast cancer during diﬀerent interventions and even after
the end of therapy may, thus, be speculated to be a harbinger
for recurrence of the disease.
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